Scientific Sessions 2026 Industry Programming Guide

12 Listings current as of Tuesday, Oct. 13, 2026. View the Mobile Meeting Guide App for more details. What We Don’t Do, What We Don’t See, What Comes Next: Device Therapy in Heart Failure 12:30–1:15 p.m. Heart Theater 2 SUPPORTER: Medtronic, Inc. A Novel Aldosterone-Targeted Treatment for Patients With Uncontrolled Hypertension 12:30–1:15 p.m. Learning Studio 1 SUPPORTER: AstraZeneca Unaddressed Risks: RAAS Dysregulation & the Role of Aldosterone in HF 12:30–1:15 p.m. Learning Studio 2 SUPPORTER: Boehringer Ingelheim Pharmaceuticals, Inc. CRISPR-Based Gene Editing: Expanding Horizons in Cardiac Care 12:30–1:15 p.m. Learning Studio 3 SUPPORTER: Intellia Therapeutics, Inc. Closing the Gap: Advancing Guideline-Directed Lipid Management and Treatment Intensification for High-Risk Patients 12:30–1:15 p.m. Learning Studio 4 SUPPORTER: Novartis Pharmaceutical Corporation Implementation in Action: Closing the Gap in ASCVD 12:30–1:15 p.m. Learning Studio 5 SUPPORTER: Amgen Inc. Obstructive HCM: Translating Evidence Into Practice 12:30–1:15 p.m. CardioTalk 2 SUPPORTER: Bristol Myers Squibb Advancing Lp(a) Care Through Shared Decision-Making 1:30–2 p.m. CardioTalk 2 SUPPORTER: (Heart) Implementation Science (QORA) Beyond Traditional HCM: Understanding Cardiac Disease Progression in Friedreich Ataxia 1:45–2:30 p.m. Heart Theater 1 SUPPORTER: Lexeo Therapeutics, Inc. Beyond Weight: Organ Crosstalk Throughout the Cardiometabolic Continuum 1:45–2:30 p.m. Learning Studio 3 SUPPORTER: Boehringer Ingelheim Pharmaceuticals, Inc. New Data on ATTR-CM for Healthcare Providers From CARDIO-TTRansform 1:45–2:30 p.m. Learning Studio 4 SUPPORTER: AstraZeneca Connecting at the Point of Care: Leveraging Industry Innovation With Integrated CKM Care Delivery 2–2:45 p.m. Industry Room N427D SPONSOR: (Heart) CardiovascularKidney-Metabolic Syndrome Seeing Women With Aortic Stenosis More Clearly: What SMART Reveals at 3 Years 3–3:30 p.m. CardioTalk 2 SUPPORTER: Medtronic, Inc. Diagnosing, Staging and Treating CAD - The TRANSFORM Trial 3:15–4 p.m. Learning Studio 3 SUPPORTER: Cleerly, Inc The Heart of CV Inflammation: Evidence and Evolving Science 3:15–4 p.m. Learning Studio 4 SUPPORTER: Novo Nordisk, Inc. Detecting ATTR-CM Before Heart Failure: The Next Frontier in Precision Cardiomyopathy 3:15–4:30 p.m. Industry Room N427D SUPPORTER: Pfizer Inc. 2026 INDUSTRY EVENTS Saturday, Nov. 7

RkJQdWJsaXNoZXIy MjI2NjI=